News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Depomed, Inc. (DEPO) And Madaus S.r.l. Announce Acceptance Of The Application For Approval Of ProQuin(R) XR In Sweden


3/29/2006 12:09:49 PM

MENLO PARK, Calif. & PADOVA, Italy--(BUSINESS WIRE)--March 29, 2006--Depomed, Inc. (Nasdaq:DEPO) and Madaus S.r.l. today announced that the Marketing Authorization Application (MAA) for ProQuin(R) XR was accepted for review by the Medical Products Agency in Sweden. Madaus submitted the MAA earlier this year, seeking approval for ProQuin XR for the treatment of uncomplicated urinary tract infections. ProQuin XR is a once-daily, prolonged release formulation of ciprofloxacin hydrochloride, which was developed by Depomed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES